February 2018
Starting March 1, 2018, prescriptions for all growth hormone products will have mandatory prior authorization requirements
At Blue Cross Blue Shield of Michigan and Blue Care Network, we regularly review drug therapies as an extra safeguard to ensure we cover the right medication for the right situation.
Beginning March 1, 2018, growth hormone products will require approval before Blue Cross and BCN will cover them under their prescription drug plan.
A few points to remember
- Drug approval requirements for coverage and all drug lists can be found online at bcbsm.com/pharmacy.
- Pediatric members and adult members have different coverage requirements.
- We cover nonpreferred growth hormone products after the member tries all preferred products and finds them not effective.
Here’s the copayment levels for growth hormone products:
Higher cost (nonpreferred) drugs |
Copayment level |
3-tier benefit |
4-tier benefit |
5-tier and 6-tier benefits |
Humatrope® |
Nonpreferred brand
(tier 3) |
Specialty
(tier 4) |
Nonpreferred specialty
(tier 5) |
Omnitrope® |
Saizen®, Saizenprep® |
Serostim® |
Zomacton™ |
Lower cost (preferred) alternatives |
3-tier benefit |
4-tier benefit |
5-tier and 6-tier benefits |
Genotropin® |
Preferred brand
(tier 2) |
Specialty
(tier 4) |
Preferred specialty
(tier 4) |
Norditropin® FlexPro®
(will be preferred effective March 1, 2018) |
Nutropin AQ® Nuspin™ |
|